Belgian firm UCB sells Chinese neurology and allergy business to CBC and Mubadala for $680m.
Belgian biopharmaceutical firm UCB is selling its Chinese neurology and allergy business to Singapore-based CBC and Abu Dhabi's Mubadala for $680m. The deal includes UCB's neurology portfolio and anti-allergy medicines, as well as a manufacturing site in Zhuhai city. This sale will enable UCB to focus on innovation and partnerships in China, as it aligns its strategic goals with the evolving demands of the Chinese market.
August 26, 2024
55 Articles